Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Egalet Corp (EGLTQ)

OTC Markets
Currency in USD
Disclaimer
0.01
0.00(0.00%)
Closed

EGLTQ Comments

Egalet (NASDAQ: EGLT) came public in 2014 and has a market capitalization of just $200 million at the moment. Its primary drug candidate is an abuse resistant pain compound called ARYMO ER that has an October 14th PDUFA date. Approval is highly likely as ARYMO ER was recommended for approval in early August by its Ad Comm panel by an 18 to 1 vote. The shares could also be helped this week as Pain Therapeutics’ (NASDAQ: PTIE) application for pain management drug Remoxy ER was rejected by the FDA which cratered its stock and might have investors looking for alternatives in the space. The stock of Egalet sells for just under $8 a share currently. Cantor Fitzgerald reiterated a Buy rating and $21 price target on the shares earlier in September.
1.60 on july6
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.